This is an I-Heart podcast.

Guaranteed Human.

Welcome to Wellness and Mass.

I'm Dr. Nicole Sapphire, and I have an interesting topic to talk to you about today.

I'm not sure if you caught the press conference over the weekend,

but President Trump, straight from the Oval Office, was working on Saturday morning.

And he had a lot of people behind him, including Secretary Kennedy, FDA Commissioner McCarrie.

And he also had Joe Rogan behind him.

Now, what were they all doing in the Oval Office on a beautiful Saturday?

Well, it kind of felt like we were being transported back to the 1970s. Now, what do I mean by that?

Well, because they were talking about psychedelic medications. And this executive order is aimed

at accelerating research and access to medications like psilocybin, MDMA, LSD. I'm not sure if

you knew that, but yeah, we have been studying these for decades in how

that they may be able to help us with addiction and refractory cases of mental illness.

Now, one that's specifically getting a lot of attention right now from the Oval Office is Ibegin.

Ibogin is a little bit different than the others.

While most psychedelics that have been

studied, like psilocybin and MDMA, they primarily work through serotonin pathways, and they've been

used for depression, PTSD. Ibrahimagane has a much broader pharmacologic profile. Not only does it

interact with serotonin, but also opioid receptors and

dopamine receptors. So, well, before we can jump into what this executive order even does,

I want to take a step back for a minute because when we talk about mental health and the

...